ArticleStem cells (Dayton, Ohio)2010
A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy.
Article in Stem cells (Dayton, Ohio), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- Cell and gene therapy in neuro-oncology.Handbook of clinical neurology · 2024Review
- Utilizing induced neural stem cell-based delivery of a cytokine cocktail to enhance chimeric antigen receptor-modified T-cell therapy for brain cancer.Bioengineering & translational medicine · 2023Article
- Magnetic Control of Protein Expression via Magneto-mechanical Actuation of ND-PEGylated Iron Oxide Nanocubes for Cell Therapy.ACS applied materials & interfaces · 2023Article
- Gene Therapy for High Grade Glioma: The Clinical Experience.Expert opinion on biological therapy · 2023Review
- Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence.Molecular therapy oncolytics · 2022Article
- TRAIL/S-layer/graphene quantum dot nanohybrid enhanced stability and anticancer activity of TRAIL on colon cancer cells.Scientific reports · 2022Article
- Review
- Delivery strategies for cell-based therapies in the brain: overcoming multiple barriers.Drug delivery and translational research · 2021Article
- The MUDENG Augmentation: A Genesis in Anti-Cancer Therapy?International journal of molecular sciences · 2020Review
- Generation and Profiling of Tumor-Homing Induced Neural Stem Cells from the Skin of Cancer Patients.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Developing Implantable Scaffolds to Enhance Neural Stem Cell Therapy for Post-Operative Glioblastoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection.PloS one · 2018Article
- Space Invaders: Brain Tumor Exploitation of the Stem Cell Niche.The American journal of pathology · 2018Review
- Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors.Scientific reports · 2017Article
- Tumor-homing cytotoxic human induced neural stem cells for cancer therapy.Science translational medicine · 2017Article
- Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma.Biomaterials · 2016Article
- Neural stem cell therapy for cancer.Methods (San Diego, Calif.) · 2016Review
- Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer.Biomaterials · 2016Article
- Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma.Nature communications · 2016Article
- Exogenous marker-engineered mesenchymal stem cells detect cancer and metastases in a simple blood assay.Stem cell research & therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Stem cells are promising therapeutic delivery vehicles; however pre-clinical and clinical applications of stem cell-based therapy would benefit significantly from the ability to simultaneously determine therapeutic efficacy and pharmacokinetics of therapies delivered by engineered stem cells. In this study, we engineered and screened numerous fusion variants that contained therapeutic (TRAIL) and diagnostic (luciferase) domains designed to allow simultaneous investigation of multiple events in stem cell-based therapy in vivo. When various stem cell lines were engineered with the optimized molecule, SRL(O)L(2)TR, diagnostic imaging showed marked differences in the levels and duration of secretion between stem cell lines, while the therapeutic activity of the molecule showed the different secretion levels translated to significant variability in tumor cell killing. In vivo, simultaneous diagnostic and therapeutic monitoring revealed that stem cell-based delivery significantly improved pharmacokinetics and anti-tumor effectiveness of the therapy compared to intravenous or intratumoral delivery. As treatment for highly malignant brain tumor xenografts, tracking SRL(O)L(2)TR showed stable stem cell-mediated delivery significantly regressed peripheral and intracranial tumors. Together, the integrated diagnostic and therapeutic properties of SRL(O)L(2)TR answer critical questions necessary for successful utilization of stem cells as novel therapeutic vehicles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.